Overview

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the clinical effects of the investigational drug, SB-509, in subjects with diabetic neuropathy.
Phase:
Phase 2
Details
Lead Sponsor:
Sangamo Biosciences
Sangamo Therapeutics
Collaborator:
Juvenile Diabetes Research Foundation